Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$97.53 -1.0%	$97.48	$76.53 ▼ $131.49	$23.45B	1.35	918,266 shs	510,755 shs
ONC Beigene	$240.41 +0.9%	$240.14	$141.31 ▼ $287.88	$23.81B	0.35	462,101 shs	189,191 shs
RVMD Revolution Medicines	$37.73 +2.1%	$37.53	$29.17 ▼ $62.40	$7.03B	1.11	1.51 million shs	2.27 million shs
TEVA Teva Pharmaceutical Industries	$18.13 +2.4%	$15.47	$12.47 ▼ $22.80	$20.56B	0.62	10.03 million shs	11.47 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.13%	-3.12%	-3.40%	-13.53%	+1.65%
ONC Beigene	-1.29%	+0.61%	-2.69%	-7.99%	+23,830,999,900.00%
RVMD Revolution Medicines	-7.04%	-8.65%	-4.64%	-8.72%	-2.58%
TEVA Teva Pharmaceutical Industries	+4.57%	+5.79%	+19.09%	+5.54%	+6.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.609 of 5 stars	4.4	2.0	0.0	0.0	3.1	0.8	0.0
ONC Beigene	2.8965 of 5 stars	4.5	0.0	0.0	0.0	1.8	1.7	0.6
RVMD Revolution Medicines	4.2549 of 5 stars	4.5	0.0	0.0	4.7	3.6	2.5	0.0
TEVA Teva Pharmaceutical Industries	2.592 of 5 stars	3.6	3.0	0.8	0.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.89	Moderate Buy	$141.73	45.32% Upside
ONC Beigene	3.00	Buy	$319.00	32.69% Upside
RVMD Revolution Medicines	3.00	Buy	$67.08	77.80% Upside
TEVA Teva Pharmaceutical Industries	3.11	Buy	$24.50	35.14% Upside

Current Analyst Ratings Breakdown

Latest RVMD, BNTX, ONC, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $134.00
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
5/8/2025	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00
5/8/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $80.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.75B	8.54	$4.19 per share	23.25	$92.17 per share	1.06
ONC Beigene	$4.18B	5.70	N/A	N/A	$37.10 per share	6.48
RVMD Revolution Medicines	$742K	9,471.55	N/A	N/A	$11.09 per share	3.40
TEVA Teva Pharmaceutical Industries	$16.62B	1.24	$3.59 per share	5.05	$4.75 per share	3.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	$1.01B	-$3.40	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	8/4/2025 (Estimated)
ONC Beigene	-$881.71M	-$3.72	N/A	338.61	7.73	-25.94%	-25.12%	-14.95%	N/A
RVMD Revolution Medicines	-$436.37M	-$4.00	N/A	N/A	N/A	N/A	-33.67%	-30.08%	8/6/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.89	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)

Latest RVMD, BNTX, ONC, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ONC Beigene	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
3/10/2025	Q4 2024	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.57%	N/A	N/A	N/A
ONC Beigene	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.58%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.33	7.21
ONC Beigene	0.05	1.93	1.72
RVMD Revolution Medicines	N/A	14.24	14.24
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
ONC Beigene	48.55%
RVMD Revolution Medicines	94.34%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
ONC Beigene	6.62%
RVMD Revolution Medicines	8.20%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	3,080	240.39 million	193.71 million	Optionable
ONC Beigene	9,000	99.05 million	90.59 million	N/A
RVMD Revolution Medicines	250	186.27 million	154.76 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

RVMD, BNTX, ONC, and TEVA Headlines

Recent News About These Companies

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

May 28 at 12:11 PM | zacks.com

FDA fast-tracks Teva's coeliac disease treatment

May 28 at 8:33 AM | pharmaphorum.com

Capital A Wealth Management LLC Invests $596,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 28 at 6:26 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408

May 27 at 9:28 PM | insidermonkey.com

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

May 27 at 5:30 PM | globenewswire.com

Teva initiated with bullish view at Truist, here's why

May 27 at 4:33 PM | https://thefly.com

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

May 27 at 4:30 PM | globenewswire.com

Why Is Teva Stock Trading Higher On Tuesday?

May 27 at 3:44 PM | benzinga.com

TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?

May 27 at 12:21 PM | zacks.com

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

May 27 at 8:30 AM | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 36,454 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 27 at 4:46 AM | marketbeat.com

Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)

May 26 at 10:13 AM | finance.yahoo.com

Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)

May 26 at 10:13 AM | insidermonkey.com

Royal Bank of Canada Increases Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 26 at 4:07 AM | marketbeat.com

Man Group plc Has $954,000 Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 26 at 3:54 AM | marketbeat.com

Two Sigma Investments LP Sells 28,694 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 25 at 4:23 AM | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Rating Increased to Buy at Wall Street Zen

May 24, 2025 | marketbeat.com

Worldquant Millennium Advisors LLC Invests $4.96 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 24, 2025 | marketbeat.com

Why Investors Should Watch Teva Despite Regional Risks

May 23, 2025 | seekingalpha.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Two Sigma Advisers LP

May 23, 2025 | marketbeat.com

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

May 22, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Turbulence for Joby Shares: What's Behind the Recent Dip?
By Jeffrey Neal Johnson | May 22, 2025
View Turbulence for Joby Shares: What's Behind the Recent Dip?
Palantir Earnings: 1 Bullish Signal and 1 Area of Concern
By Chris Markoch | May 2, 2025
View Palantir Earnings: 1 Bullish Signal and 1 Area of Concern
3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
By Leo Miller | May 27, 2025
View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
Joby Just Flew Two Aircraft at Once—Here’s Why It Matters
By Jeffrey Neal Johnson | May 14, 2025
View Joby Just Flew Two Aircraft at Once—Here’s Why It Matters
Advance Auto Parts: Did Earnings Defuse Tariff Concerns?
By Gabriel Osorio-Mazilli | May 28, 2025
View Advance Auto Parts: Did Earnings Defuse Tariff Concerns?

RVMD, BNTX, ONC, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

$97.53 -1.02 (-1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$97.00 -0.53 (-0.54%)

As of 07:38 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Beigene NASDAQ:ONC

$240.41 +2.10 (+0.88%)

As of 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Revolution Medicines NASDAQ:RVMD

$37.73 +0.76 (+2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$37.40 -0.33 (-0.89%)

As of 07:09 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Teva Pharmaceutical Industries NYSE:TEVA

$18.13 +0.42 (+2.37%)

Closing price 03:59 PM Eastern

Extended Trading

$18.23 +0.10 (+0.52%)

As of 07:59 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time